Table of Content

1. Report Introduction

2. Primary Biliary Cholangitis
2.1. Primary Biliary Cholangitis Disease Overview
2.2. Primary Biliary Cholangitis History
2.3. Primary Biliary Cholangitis Symptoms
2.4. Primary Biliary Cholangitis Causes
2.5. Primary Biliary Cholangitis Pathophysiology
2.6. Primary Biliary Cholangitis Diagnosis
2.6.1. Diagnostic Guidelines

3. Primary Biliary Cholangitis Current Treatment Patterns
3.1. Treatment Guidelines

4. Primary Biliary Cholangitis - DelveInsight’s Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Primary Biliary Cholangitis companies collaborations, Licensing, Acquisition –Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Primary Biliary Cholangitis Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Primary Biliary Cholangitis Acquisition Analysis
4.2. Clinical Assessment of Pipeline Drugs
4.2.1. Assessment by Phase of Development
4.2.2. Assessment by Product Type (Mono / Combination)
4.2.2.1. Assessment by Stage and Product Type
4.2.3. Assessment by Route of Administration
4.2.3.1. Assessment by Stage and Route of Administration
4.2.4. Assessment by Molecule Type
4.2.4.1. Assessment by Stage and Molecule Type
4.2.5. Assessment by MOA
4.2.5.1. Assessment by Stage and MOA

5. Primary Biliary Cholangitis Pipeline Therapeutics
5.1. Late Stage Products (Phase-III)
5.1.1. Comparative Analysis
5.2. Mid Stage Products (Phase-II)
5.2.1. Comparative Analysis
5.3. Early Stage Products (Phase-I)
5.3.1. Comparative Analysis
5.4. Pre-clinical and Discovery Stage Products
5.4.1. Comparative Analysis
5.5. Inactive Products

6. Primary Biliary Cholangitis -Products Analysis
6.1. Product Profiles
6.1.1. CymaBay Therapeutics- Seladelpar
6.1.1.1. Product Description
6.1.1.1.1. Product Overview
6.1.1.1.2. Mechanism of Action
6.1.1.2. Research and Development
6.1.1.2.1. Clinical Studies
6.1.1.2.1.1. Detailed Study Description
6.1.1.2.1.2. Study Results
6.1.1.2.1.3. Clinical Trials: Tabular View
6.1.1.3. Product Development Activities
6.1.1.3.1. Tabulated Product Summary
6.1.1.3.1.1. General Description Table
6.1.2. Fast Forward Pharmaceuticals- FFP104
6.1.2.1. Product Description
6.1.2.1.1. Product Overview
6.1.2.1.2. Mechanism of Action
6.1.2.2. Research and Development
6.1.2.2.1. Clinical Studies
6.1.2.2.1.1. Detailed Study Description
6.1.2.2.1.2. Study Results
6.1.2.2.1.3. Clinical Trials: Tabular View
6.1.2.3. Product Development Activities
6.1.2.3.1. Tabulated Product Summary
6.1.2.3.1.1. General Description Table
6.1.3. Enanta Pharmaceuticals- EDP-305
6.1.3.1. Product Description
6.1.3.1.1. Product Overview
6.1.3.1.2. Mechanism of Action
6.1.3.2. Research and Development
6.1.3.2.1. Clinical Studies
6.1.3.2.1.1. Detailed Study Description
6.1.3.2.1.2. Study Results
6.1.3.2.1.3. Clinical Trials: Tabular View
6.1.3.3. Product Development Activities
6.1.3.3.1. Tabulated Product Summary
6.1.3.3.1.1. General Description Table
To be continued in the report??????????

7. Recent Technologies

8. Primary Biliary Cholangitis Key Companies
8.1. Enanta Pharmaceuticals
8.2. Eli Lilly/Incyte Corporation
8.3. NGM Biopharmaceuticals
8.4. GlaxoSmithKline
8.5. Fast Forward Pharmaceuticals
8.6. GenKyoTex
8.7. Albireo AB
8.8. CymaBay Therapeutics
8.9. Zydus Cadila
8.10. Genfit

9. Primary Biliary Cholangitis Key Products
9.1. EDP 305
9.2. Baricitinib
9.3. Linerixibat
9.4. Setanaxib
9.5. Odevixibat
9.6. Seladelpar
9.7. Saroglitazar
9.8. Elafibranor
9.9. Linerixibat
9.10. FFP104

10. Dormant and Discontinued Products
10.1. Dormant Products
10.1.1. Reasons for being dormant
10.2. Discontinued Products
10.2.1. Reasons for the discontinuation

11. Primary Biliary Cholangitis - Unmet Needs

12. Primary Biliary Cholangitis - Future Perspectives

13. Appendix

14. Report Methodology
14.1. Secondary Research
14.2. Expert Panel Validation



List of Figures


Figure 1. Disease Overview
Figure 2. History
Figure 3. Symptoms
Figure 4. Causes
Figure 5. Pathophysiology
Figure 6. Diagnostic Guidelines
Figure 7. Treatment Guidelines
Figure 8. Primary Biliary Cholangitis companies collaborations, Licensing, Acquisition –Deal Value Trends
Figure 9. Company-Company Collaborations (Licensing / Partnering) Analysis
Figure 10. Primary Biliary Cholangitis Acquisition Analysis
Figure 11. Assessment by Phase of Development
Figure 12. Assessment by Product Type (Mono / Combination)
Figure 13. Assessment by Stage and Product Type
Figure 14. Assessment by Route of Administration
Figure 15. Assessment by Stage and Route of Administration
Figure 16. Assessment by Molecule Type
Figure 17. Assessment by Stage and Molecule Type
Figure 18. Assessment by MOA
Figure 19. Assessment by Stage and MOA
Figure 20. Late Stage Products (Phase-III)
Figure 21. Mid Stage Products (Phase-II)
Figure 22. Early Stage Products (Phase-I)
Figure 23. Pre-clinical and Discovery Stage Products
Figure 24. Inactive Products
Figure 25. Dormant Products
Figure 26. Discontinued Products
Figure 27. Unmet Needs


List of Tables


Table 1. Primary Biliary Cholangitis Diagnostic Guidelines
Table 2. Treatment Guidelines
Table 3. Assessment Summary
Table 4. Company-Company Collaborations (Licensing / Partnering) Analysis
Table 5. Primary Biliary Cholangitis Acquisition Analysis
Table 6. Assessment by Phase of Development
Table 7. Assessment by Product Type (Mono / Combination)
Table 8. Assessment by Stage and Product Type
Table 9. Assessment by Route of Administration
Table 10. Assessment by Stage and Route of Administration
Table 11. Assessment by Molecule Type
Table 12. Assessment by Stage and Molecule Type
Table 13. Assessment by MOA
Table 14. Assessment by Stage and MOA
Table 15. Late Stage Products (Phase-III)
Table 16. Mid Stage Products (Phase-II)
Table 17. Early Stage Products (Phase-I)
Table 18. Pre-clinical and Discovery Stage Products
Table 19. Inactive Products
Table 20. Dormant Products
Table 21. Discontinued Products